Understanding Tysabri and PML: Key Symptoms and Documentation

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Legal Action

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like vision changes, weakness, or confusion, you may be concerned about progressive multifocal leukoencephalopathy (PML). Understanding the early signs and proper documentation is critical. This page provides plain-language facts on PML symptoms, onset timing, and what records to keep, building on decades of medical research into biologic therapies and their risks.

Understanding Tysabri and Its Risks

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning identifies three known risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, and balance disorder among the most frequently reported adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms overlap with multiple sclerosis itself, any new or worsening neurological signs should prompt immediate evaluation for PML. The prescribing information instructs healthcare professionals to monitor patients on TYSABRI for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis of PML typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. The risk of PML is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have a history of prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Due to the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse TYSABRI (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML continues to occur in treated patients, raising questions about the adequacy of warnings and risk communication.

Statute of Limitations for Tysabri Claims in Pennsylvania

For patients in Pennsylvania who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. PML may develop months to years after starting therapy, with risk increasing beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be insidious, and diagnosis can be delayed, which affects when the statute of limitations begins to run. Affected patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances, including the date of diagnosis and any prior knowledge of the link between Tysabri and PML. Attorney-related considerations for affected patients include evaluating whether the manufacturer provided adequate warnings about PML risk. The boxed warning clearly states that TYSABRI increases the risk of PML and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients may argue that the warnings were insufficient to convey the severity or likelihood of PML, or that healthcare providers failed to adequately monitor for early signs. The TOUCH program is designed to ensure informed consent, but questions may arise about whether patients truly understood the risks. Additionally, the FAERS data show that PML is not the only serious adverse event associated with Tysabri; herpes encephalitis and meningitis have also been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These infections can be life-threatening and may further complicate the clinical picture. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors identified in the prescribing information. Patients in Pennsylvania who develop PML should be aware of the statute of limitations and seek legal counsel promptly. The timeline between exposure and harm, combined with the need for timely diagnosis, underscores the importance of early legal evaluation. The adequacy of warnings and the role of the TOUCH program are central to any potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary, and diagnosis may be delayed, so it is crucial to consult an attorney promptly.

What are the known risk factors for PML in Tysabri patients?

The prescribing information identifies three known risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.